0001628280-26-016491
SEC filingADC Therapeutics S.A. reported a net loss of $142.6 million for fiscal year 2025, driven by an operating loss of $121.5 million. Total revenue was $81.4 million, consisting entirely of license revenues and royalties, with no product revenue disclosed separately. Operating expenses totaled $202.9 million, dominated by research and development costs of $104.0 million. The company generated negative operating cash flow of $141.2 million but raised $150.9 million through financing activities, primarily from equity offerings. As of December 31, 2025, the company had $278.6 million in cash and cash equivalents, total assets of $323.1 million, and shareholders' deficit of $185.8 million. The company continues to operate at a loss while maintaining significant cash reserves through equity financing.
ADC Therapeutics S.A. reported a net loss of $142.6 million for fiscal year 2025, representing a significant financial deficit. The company generated total revenue of $81.4 million, which consisted entirely of license revenues and royalties. Operating expenses totaled $202.9 million, resulting in an operating loss of $121.5 million. The company's net loss per share was $1.00 for both basic and diluted calculations. The financial results reflect continued investment in research and development while operating at a substantial loss.
The company reported total revenue of $81.4 million for fiscal year 2025. According to the XBRL data, this revenue consisted of license revenues and royalties of $81.4 million. The document indicates revenue of $81.4 million from the United States and $81.4 million from EMEA regions, though these appear to be the same total figure rather than separate segment contributions. No product revenue was separately disclosed, suggesting the company's revenue stream is primarily derived from licensing arrangements rather than direct product sales.
The company reported a gross profit figure was not explicitly disclosed in the provided data. Operating margin was negative due to the operating loss of $121.5 million on revenue of $81.4 million. Cost of product sales was $5.8 million, while research and development expenses represented the largest operating expense at $104.0 million. Selling and marketing expenses were $43.4 million, and general and administrative expenses were $36.6 million. The company also incurred restructuring, impairment and other related costs of $13.1 million.
The company used $141.2 million in cash from operating activities during fiscal year 2025. Investing activities provided $395,000, while financing activities provided $150.9 million primarily from equity offerings. Cash and cash equivalents decreased by $10.2 million to $278.6 million at year-end. Total assets were $323.1 million, with current assets of $306.3 million. Total liabilities were $509.0 million, including deferred royalty obligations of $322.5 million and senior secured term loans of $115.5 million. Shareholders' deficit was $185.8 million.
The provided document content does not include management guidance, strategic priorities, or specific risk factors that would typically appear in the Management Discussion & Analysis section of a 10-K filing. The XBRL data and document content provided focus exclusively on historical financial results without forward-looking statements. Investors should refer to the complete 10-K filing for management's discussion of future prospects, strategic initiatives, and risk factors that may affect the company's performance.